Esperion Therapeutics, Inc. Announces The Appointment Of Antonio M. Gotto Jr., M.D., Dphil, As Director
Published: Jan 13, 2014
Esperion Therapeutics, Inc. (Nasdaq: ESPR), a clinical-stage biopharmaceutical company focused on developing and commercializing first-in-class, oral, low-density lipoprotein cholesterol (LDL-C) lowering therapies for the treatment of hypercholesterolemia, today announced the appointment of Antonio M. Gotto Jr., M.D., DPhil as a Director of the Company. Dr. Gotto will serve as a Class II director with a term of office expiring at our 2015 annual meeting of stockholders.
Help employers find you! Check out all the jobs and post your resume.